Ematologia 2018: Leucemie/Linfomi Anemie Disordini della ... · University of Milano Bicocca,...
Transcript of Ematologia 2018: Leucemie/Linfomi Anemie Disordini della ... · University of Milano Bicocca,...
University of Milano Bicocca, Monza, Italy
Ematologia 2018:
Leucemie/Linfomi Anemie
Disordini della coagulazione e delle piastrine
ESAME: 23 Aprile 2018
University of Milano Bicocca, Monza, Italy
LEZIONI: http://www.ilte-cml.org/listing/Odonto/
University of Milano Bicocca, Monza, Italy
INSUFFICIENZA FUNZIONALE
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
LEUCEMIE
University of Milano Bicocca, Monza, Italy
Men
290,890
Women
272,810
26% Lung and bronchus
15% Breast
10% Colon and rectum
6% Pancreas
6% Ovary
4% Leukemia
3% Non-Hodgkin’s lymphoma
3% Uterine corpus
2% Brain/nervous system
2% Multiple myeloma
22% All other sites
Lung and bronchus 33%
Prostate 10%
Colon and rectum 10%
Pancreas 5%
Leukemia 4% Non-Hodgkin’s lymphoma 4% Esophagus 4%
Liver/intrahepatic bile duct 3%
Urinary bladder 3%
Kidney 3%
All other sites 21%
Leukemia Comprises a Vast Proportion of Cancer Deaths in the
United States
University of Milano Bicocca, Monza, Italy
Incidence of Hematologic Malignancies
Type of Leukemia Incidence per 100,000*
Overall 10–14 CML 2–3 CLL 4–5 AML 3–4 ALL 1–2
University of Milano Bicocca, Monza, Italy
Incidence and Mortality Associated With Leukemias (United States, 2003)
Incidence Mortality
Overall AML CLL CML ALL
35,000
30,000
25,000
20,000
15,000
10,000
5000
0
35,000
30,000
25,000
20,000
15,000
10,000
5000
0
33,440
11,920
8,190
4,600 3,830
23,300
8,870
4,800
1,570 1,450
University of Milano Bicocca, Monza, Italy
Leucemia Mieloide Cronica
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
PATOGENESI
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
Cytogenetic Abnormality of CML: The Philadelphia Chromosome
University of Milano Bicocca, Monza, Italy
The Philadelphia Chromosome: t(9;22) Translocation
22
bcr
abl
Ph
bcr-abl
FUSION PROTEIN WITH TYROSINE KINASE ACTIVITY
9 9+
University of Milano Bicocca, Monza, Italy
Bcr-Abl Signal Transduction Pathways
Adapted from Pasternak G et al. J Cancer Res Clin Oncol. 1998;124:643-660.
Bcr-Abl
BCL 2 inhibition of apoptosis
MYC GRB2 CRKL CBL (p120CBL)
RAS
RAF-MEK-MAPK cascade regulates cell cycle progression and differentiation
activates
JAK/STATs
upregulation of
Paxillin (Adhesion) PI-3 kinase
Actin (Adhesion)
University of Milano Bicocca, Monza, Italy
Chromosome
in Hematologic Malignancies
Leukemia % of Ph+ Patients
CML 95
ALL (Adult) 15–30
ALL (Pediatric) 5
AML 2
Faderl S et al. Oncology (Huntingt). 1999;13:169-184.
University of Milano Bicocca, Monza, Italy
DIAGNOSI
University of Milano Bicocca, Monza, Italy
CML: Peripheral Blood Smear
CML Hoffbrand AV, Pettit JE, eds. In: Color Atlas of Clinical Hematology. 2nd ed. Mosby-Wolfe; 1994:198.
University of Milano Bicocca, Monza, Italy
Epidemiology of CML
Median age range at presentation: 45 to 55 years
Incidence increases with age - 12%–30% of patients are >60 years old
Male-to-female ratio—1.3:1
University of Milano Bicocca, Monza, Italy
Clinical Presentation of CML
At presentation:
50% diagnosed by routine laboratory tests 85% diagnosed during chronic phase
University of Milano Bicocca, Monza, Italy
Clinical Presentation of CML
Common Symptoms Common Signs Fatigue Palpable splenomegaly Weight loss/anorexia Abdominal fullness Common Laboratory Findings Abnormal differential Anemia Leukocytosis Basophilia Thrombocytosis
University of Milano Bicocca, Monza, Italy
Clinical Course
University of Milano Bicocca, Monza, Italy
Clinical Course: Phases of CML
Chronic phase
Median 4–6 years stabilization
Accelerated phase
Median duration
up to 1 year
Blastic phase (blast crisis)
Median survival 3–6 months
Terminal phase
Advanced phases
University of Milano Bicocca, Monza, Italy
Typical Laboratory Parameters by Phase of CML
Parameter Chronic Accelerated Blastic WBC count >20 x 109/L — — Blasts 3%–10% >15% >30% Basophils >20% — Platelets or normal ↓ or ↓ Bone marrow Myeloid hyperplasia Cytogenetics Ph+ Bcr-Abl + + +
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
Nucleo Ph+
Nucleo normale
Metafase Ph+
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
M
692 bp 501 bp
Patie
nt E
.L.
BaF
3-T/
P
C Neg
ativ
e Pa
tient
TM HLH TKD
308 bp
533 bp
B.
C.
501 bp 692 bp
M 10-1 10-2 10-3 10-4 10-5 10-6 C U
University of Milano Bicocca, Monza, Italy
TERAPIA
Therapy of CML: Response Criteria
Hematologic Response Cytogenetic Response Complete: Major: Normal peripheral blood count Complete: 0% Ph+ cells WBC <10 x 109/L Partial: 1%–34% Ph+ cells Platelets <450 x 109/L Minor: 35%–95%
Ph+ cells No immature cells
Ph+=Philadelphia chromosome-positive.
University of Milano Bicocca, Monza, Italy
IMATINIB
Tyrosine Kinase Inhibitor
for CML
University of Milano Bicocca, Monza, Italy
Structure of imatinib
Class: Phenylaminopyrimidines, 589.7 mw
CH3SO3H
O
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
PATIENTS ENROLLED
3-10
28-46
128-151
384
Numbers of deaths compared to available rates in the italian population
MORTALITY
gender eligible O=Observed E=Expected SIR 95% CI - inf
95% CI - sup p-value
M 487 24.0 33.7 0.71 0.46 1.06 0.14
F 345 17.0 14.3 1.19 0.69 1.90 0.54
TOTAL 832 41.0 48.0 0.85 0.61 1.16 0.42
Only 10 out of 41 observed death (24.4 %) were caused by progression of CML
Survival at 8 years was 95.2% (95%CI=92.5% to 98.1%)
Survival is not statistically different from that of the general population
Rates in the Italian population are referred to ISAT 2004
University of Milano Bicocca, Monza, Italy
BMT activity for CML in Eurolandia
0
200
400
600
800
1000
1200
1400
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
total
V.U.D.
0
50000
100000
150000
200000
250000
300000
350000
400000
2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050
Prev
alen
ce
Year
Incidence 2000: 1/100.000Incidence 2000: 1,5/100.000Incidence 2000: 2/100.000
Projection of CML Prevalence Up to 2050 Assumptions: Population: 500 Mill., mortality: 2% per year, Incidence increasing by about 0.01/100.000 per year
20%-25% increase per year in projected prevalence
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
Decreasing residual leukemia
Num
ber of leukemia cells (log
10 )
0
1
2
3
4
5
6
7
8
9
10
11
12
13
0
6.0
5.0
4.0
3.0
1.0
0
Log
redu
ctio
n fr
om b
asel
ine Leukocytosis
RQ-PCR positive
RQ-PCR negative
Ph-chromosome pos
Ph-negative but…
Cure ?
BCR-ABL transcript numbers expressed as log reduction in patients responding to treatment
2.0
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
ACUTE LEUKEMIAS
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
Table 46.2-1 Diagnosis and Evaluation of Acute Leukemia -------------------------------------------------------------------
Symptoms
Fatigue, malaise, dyspnea Easy bruisability, weight loss
Bone pain or abdominal pain (less common) Neurologic symptoms (rare)
Signs Anemia and pallor
Thrombocytopenia, hemorrhage, ecchymoses, petechiae, fundal hemorrhage
Fever and infection (pneumonia, sepsis, perirectal abscess) Adenopathy, hepatosplenomegaly, mediastinal mass
Gum or skin infiltration (rare) Renal enlargement and insufficiency (rare)
Cranial neuropathy (rare)
University of Milano Bicocca, Monza, Italy
AML
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
ALL
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy
University of Milano Bicocca, Monza, Italy